Navigation Links
Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
Date:12/17/2007

t Baxter's Thrombin (Human)

Baxter's human thrombin is made from human plasma and has been a component in products used in the surgical setting for nearly 15 years.

As with all human plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses, cannot be totally eliminated.

About GELFOAM

GELFOAM is a sterile, pliable, surgical sponge prepared from specially treated, purified gelatin solution and capable of absorbing and holding within its meshes many times its weight in whole blood. It is used as a hemostatic device.

GELFOAM is a registered trademark of Pharmacia & Upjohn Company LLC.

About Baxter

Baxter Healthcare Corporation is the principal U.S. operating subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

About Pfizer Inc

Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments, and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, nearly 90,000 colleagues in more than 150 countries work every day to help people s
'/>"/>

SOURCE Baxter Healthcare Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... BEACH, Calif. , July 28, 2015 /PRNewswire-USNewswire/ ... announced that it has hit a milestone of ... Signafuse was FDA 510(k) cleared in early 2014 ... use in posterolateral spine fusion procedures.  This is ... products, as less than 6% of new synthetic ...
(Date:7/28/2015)... N.C., July 28, 2015  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2015. ... compared to the second quarter of 2014 when ... Ph.D., United Therapeutics, President and Co-Chief Executive Officer. ... an increase in the number of patients being ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: ... second quarter financial results on Thursday, July 30, 2015, ... announcement will be followed by a conference call with ... the call from Amgen will be Robert A. ... members of Amgen,s senior management team. Live ...
(Date:7/27/2015)... ... July 27, 2015 , ... This is a ... provides a basic overview of the industry including definitions, classifications, applications and industry ... development trends, competitive landscape analysis, and key regions development status. Development policies and ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Amgen Announces Webcast of 2015 Second Quarter Financial Results 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3
... - Anavex Life,Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today ... significantly delay the growth of cancerous,tumors in patient-derived ... were developed in ANAVEX labs using a sample,taken ... Clear cell sarcoma,is a rare type of melanoma ...
... YWCA & Roche to Educate Patients on, How ... a Career -, NEW YORK, March 10 ... a non-profit program,founded by Cosmetic Executive Women Foundation, and ... hundreds of thousands of people,living with cancer on how ...
... PINE BROOK, N.J., March 10 Elusys Therapeutics, ... for the treatment of life-threatening infectious,diseases, today announced ... President of Research., Elizabeth G. Posillico, Ph.D., ... "On behalf of Elusys, Board of Directors and,management, ...
Cached Biology Technology:Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 2Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 3Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 4Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 5Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity 6First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 2First-Ever 'Cancer and Careers' Seminar Debuts in Orange County 3Elusys Therapeutics Appoints Robert Gundel as Vice President of Research 2
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
(Date:6/25/2015)... -- According to a new market ... Technology, Material (Optical Prism, Piezoelectric, Capacitive & Adhesives), ... & Geography - Global Forecast to 2014 - ... expected to reach $14,500.07 Million by 2020, at ... 76 market Tables and 109 Figures spread through ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... cells influenced by embryonic stem cell-derived cells can help ... without the use of immunosuppressive drugs. The University ... Medical Center finding has implications for possible improvements in ... results appeared Friday in the online journal PLoS ...
... MABrandeis University has won a highly competitive $7.8 ... establish a Materials Research Science and Engineering Center ... imposing constraints on materials, such as DNA confined ... of rod-like virus particles, as a guide to ...
... 2008 Selenium has been referred to as an "essential ... a marginal line between the nutritious requirement and toxic ... to bioaccumulation effects have lead to the characterization of ... by exceeding a narrow threshold concentration in ecosystems through ...
Cached Biology News:Embryonic stem cells might help reduce transplantation rejection 2New research center at Brandeis to combine materials science and biology 2New research center at Brandeis to combine materials science and biology 3Biological selenium removal: The solution to pollution? 2
Request Info...
... Gelzyme is an agarose-digesting enzyme isolated ... simple carbohydrate bonds in agarose producing ... gel. The remaining carbohydrate molecules will ... DNA isolated with Gelzyme enzyme can ...
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Biology Products: